Devlin MJ

No ORCID on file · 2 papers in corpus
nonrandomized-trial 2025
JAMA oncology ·doi:10.1001/jamaoncol.2024.6797

IMPORTANCE: Advanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with programmed cell death 1 protein (PD-1) inhibitors reported…

review 2023
Therapeutic advances in medical oncology ·doi:10.1177/17588359221148024

The treatment of high-grade serous ovarian cancer and high-grade endometrioid ovarian cancer has seen significant improvements in recent years, with BRCA1/2 and homologous recombination status guiding a personalized approach which has resul…